TY - JOUR
T1 - Screening for anal cancer in women
AU - Moscicki, Anna Barbara
AU - Darragh, Teresa M.
AU - Michael Berry-Lawhorn, J.
AU - Roberts, Jennifer M.
AU - Khan, Michelle J.
AU - Boardman, Lori A.
AU - Chiao, Elizabeth
AU - Einstein, Mark H.
AU - Goldstone, Stephen E.
AU - Jay, Naomi
AU - Likes, Wendy M.
AU - Stier, Elizabeth A.
AU - Welton, Mark L.
AU - Wiley, Dorothy J.
AU - Palefsky, Joel M.
N1 - Funding Information:
Einstein's time spent for advice related to clinical trials from Merck, GSK, Roche, Photocure, Papivax, Cepheid, and PDS Biotechnologies. If travel is required for meetings with any industry, the company pays for Dr. Einstein's travel-related expenses. In addition, Montefiore has received grant funding for research-related costs of clinical trials that Dr. Einstein has been the overall PI or Montefiore PI from Merck, GSK, Roche, Photocure, Inovio, PDS Biotechnologies, Becton-Dickinson, Cepheid, and Hologic. The other authors have declared they have no conflicts of interest. This work was supported in part by the National Cancer Institute [grant number R37 CA51323] and the National Institute of Allergy and Infectious Diseases [grant number RC1 AI86051-01]. No IRB approval was necessary, since this paper reflects a review article and summary of expert opinion. Copyright © 2015 American Society for Colposcopy and Cervical Pathology ISSN: 1089-2591 DOI: 10.1097/LGT.0000000000000117 Conclusions: While there are no data yet to demonstrate that identification and treatment of anal HSIL leads to reduced risk of anal cancer, women in groups at the highest risk should be queried for anal cancer symptoms and required to have digital anorectal examinations to detect anal cancers. Human immunodeficiency virus–infected women and women with lower genital tract neoplasia may be considered for screening with anal cytology with triage to treatment if HSIL is diagnosed. Healthy women with no known risk factors or anal cancer symptoms do not need to be routinely screened for anal cancer or anal HSIL.
Publisher Copyright:
Copyright © 2015 American Society for Colposcopy and Cervical Pathology.
PY - 2015
Y1 - 2015
N2 - Objective: The incidence of anal cancer is higher in women than men in the general population and has been increasing for several decades. Similar to cervical cancer, most anal cancers are associated with human papillomavirus (HPV), and it is believed that anal cancers are preceded by anal high-grade squamous intraepithelial lesions (HSIL). Our goals were to summarize the literature on anal cancer, HSIL, and HPV infection in women and to provide screening recommendations in women. Methods: A group of experts convened by the American Society for Colposcopy and Cervical Pathology and the International Anal Neoplasia Society reviewed the literature on anal HPV infection, anal SIL, and anal cancer in women. Results: Anal HPV infection is common in women but is relatively transient in most. The risk of anal HSIL and cancer varies considerably by risk group, with human immunodeficiency virus-infected women and those with a history of lower genital tract neoplasia at highest risk compared with the general population.
AB - Objective: The incidence of anal cancer is higher in women than men in the general population and has been increasing for several decades. Similar to cervical cancer, most anal cancers are associated with human papillomavirus (HPV), and it is believed that anal cancers are preceded by anal high-grade squamous intraepithelial lesions (HSIL). Our goals were to summarize the literature on anal cancer, HSIL, and HPV infection in women and to provide screening recommendations in women. Methods: A group of experts convened by the American Society for Colposcopy and Cervical Pathology and the International Anal Neoplasia Society reviewed the literature on anal HPV infection, anal SIL, and anal cancer in women. Results: Anal HPV infection is common in women but is relatively transient in most. The risk of anal HSIL and cancer varies considerably by risk group, with human immunodeficiency virus-infected women and those with a history of lower genital tract neoplasia at highest risk compared with the general population.
UR - http://www.scopus.com/inward/record.url?scp=84991501365&partnerID=8YFLogxK
U2 - 10.1097/LGT.0000000000000117
DO - 10.1097/LGT.0000000000000117
M3 - Article
C2 - 26103446
AN - SCOPUS:84991501365
SN - 1089-2591
VL - 19
SP - S27-S42
JO - Journal of Lower Genital Tract Disease
JF - Journal of Lower Genital Tract Disease
IS - 3
ER -